# A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia

> **NCT03441555** · PHASE1 · COMPLETED · sponsor: **AbbVie** · enrollment: 36 (actual)

## Conditions studied

- Acute Myeloid Leukemia (AML)

## Interventions

- **DRUG:** Venetoclax
- **DRUG:** Alvocidib

## Key facts

- **NCT ID:** NCT03441555
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-30
- **Primary completion:** 2021-01-25
- **Final completion:** 2021-01-25
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2022-02-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03441555

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03441555, "A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03441555. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*